

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA

If you paid for some or all of the purchase price of Stelara,

You Could Be Included in a Class Action Lawsuit.

A Federal Court ordered this Class Notice.

***YOUR LEGAL RIGHTS ARE AFFECTED WHETHER YOU ACT OR DO NOT ACT, SO
PLEASE READ THIS NOTICE CAREFULLY.***

This is not a solicitation from a lawyer. You are not being sued.

- You could be affected by a class action lawsuit against Defendants Johnson & Johnson and Janssen Biotech Inc. (together, “J&J” or “the Defendants”).
- The purpose of this Notice is to alert you that the United States District Court for the Eastern District of Virginia has certified the lawsuit as a class action that includes all Third-Party Payors (“TPPs”) who indirectly purchased or paid for Stelara (“the at-issue drugs”).
- The lawsuit alleges that the Defendants engaged in a scheme in violation of state antitrust and consumer protection laws. J&J knowingly, willfully, and improperly maintained its monopoly power and substantially reduced and harmed competition in the market for ustekinumab in the United States by: (1) fraudulently obtaining a method-of-use patent to treat ulcerative colitis, (2) wrongfully acquiring the Momena biosimilar manufacturing patents, and then (3) asserting and/or enforcing those patents (the ’307 and Momena patents) against would-be competitors to unlawfully delay biosimilar competition. Defendants’ scheme delayed the entry of biosimilar competition for J&J’s brand name prescription pharmaceutical drug Stelara by at least fifteen months, causing TPPs to pay supra-competitive prices for Stelara and/or its biosimilar analogs during the relevant time period, and Plaintiffs, or the entities that sued, seek to recover damages from J&J. No one is claiming the at-issue drugs are unsafe.
- The Defendants deny these allegations, and the Court has not decided that the Defendants did anything wrong; rather, the case is currently scheduled to go to trial on January 26, 2026. There is no money available now, and whether any becomes available to anyone will depend on the outcome of the lawsuit.
- However, your legal rights are affected, and you have a choice to make now. Your options are explained in this Notice.

The Class Definition—Read Carefully

On December 5, 2025, the Court certified the following class:

Damages Class. All Third-Party Payers that indirectly purchased or paid for, as part of a prescription drug benefit, some or all of the purchase price for Stelara in the Damages Class States or Territories¹

¹ The Damages Class States or Territories are Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Maryland, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire,

for personal use by their members, enrollees or beneficiaries from January 1, 2024 through December 31, 2025 (the “class period”);

Excluded from the Class are: (a) J&J and its subsidiaries and affiliates; (b) federal and state governmental entities; and (c) Third-Party Payers whose only purchases were made pursuant to any Medicaid plan, whether Fee-for-Service or Managed Medicaid.

If you purchased or paid for all or part of the price of any of the at-issue drugs during the Class Period for those drugs as stated above, you ARE a class member. You will remain a class member if you do nothing.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS LAWSUIT	
DO NOTHING	<p>If you are a member of the Class, by doing nothing, you will remain in the Class and may be entitled to share in any recovery that may come from a trial or settlement with the Defendants for the Class. You will be bound by any Court decision in this lawsuit (including a judgment in favor of the Defendants) as to the Class, and you will give up your rights to sue any of the Defendants about the same set of facts, series of transactions, or legal claims involved in this lawsuit as to the Class.</p>
EXCLUDE YOURSELF FROM THE CLASS	<p>This is the only option that allows you to file or be part of another lawsuit against the Defendants relating to the claims in this case.</p> <p>If you are a member of the Class, you may exclude yourself from the Class. You will not be bound by any of the Court’s orders in this case if you exclude yourself. If you exclude yourself from the Class, you will keep your right to sue Defendants for the Class’s claims against the Defendants, but you will not be entitled to participate in and benefit from a recovery, if any, on behalf of the Class.</p> <p>Any dispute about your request to be excluded will be resolved by the Court.</p> <p>The deadline to exclude yourself from the lawsuit is January 22, 2026.</p>

New Mexico, New York, North Carolina, North Dakota, Oregon, Puerto Rico, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin.

**QUESTIONS? CALL 1-866-963-9975 OR VISIT
WWW.STELARATPPCLASSACTION.COM.**

**GET MORE
INFORMATION**

If you would like more information about the lawsuit, you can review this Notice and send questions to the Plaintiffs' lawyers identified in **Question 13** below.

**DO NOT CONTACT THE COURT OR THE
DEFENDANTS IF YOU HAVE QUESTIONS
REGARDING THIS NOTICE.**

BASIC INFORMATION.....	5
1. Why did I receive this Notice?	5
2. What is the lawsuit about?	5
3. Why is this lawsuit a class action?	6
THE CLAIMS IN THE LAWSUIT.....	7
4. What is the current status of the lawsuit?	7
5. Has the Court decided who is right?	7
6. What is plaintiff asking for?	7
7. Is there any money available now?	7
WHO IS IN THE CLASS?	7
8. Am I part of the Class?	8
YOUR RIGHTS AND OPTIONS AS A MEMBER OF THE CLASS.	8
9. What are my legal rights and options in this case?	8
10. What happens if I do nothing at all?	9
11. Why would I ask to be excluded from the Class?	9
12. How do I ask the Court to exclude me from the Class?	9
THE LAWYERS REPRESENTING THE CLASS.....	10
13. Do I have a lawyer in this case?	10
14. Should I hire my own lawyer?	10
15. How will the lawyers be paid?	10
THE TRIAL.....	11
16. How and when will the Court decide who is right?	11
17. Do I have to come to the trial?	11
18. Will I get money after the trial?	11
GETTING MORE INFORMATION.....	11
19. Are more details available?	11

BASIC INFORMATION

1. Why did I receive this Notice?

The Class has been “certified” in this class action lawsuit. This means that the lawsuit meets the requirements for class actions and may proceed to trial.

You received this Notice because records indicate that you may be a member of the certified Class. If you are included, you have a right to know about your rights and options before the Court holds a trial to decide whether the claims being made against J&J are correct. This notice explains all of these things.

Judge Jamar K. Walker, of the United States District Court for the Eastern District of Virginia, is currently overseeing this lawsuit. This case is known as *CareFirst of Maryland v. Johnson & Johnson*, No. 23-cv-00629. The entities who sued are called the Plaintiffs. J&J are the Defendants.

Simply receiving this Notice does not mean that you are definitely a member of the Class. You may confirm that you are a member of the Class by reviewing the criteria set forth in **Question 8** below. You may also call, email, or write to the lawyers in this case at the telephone numbers or addresses listed in **Question 13** below.

2. What is the lawsuit about?

Plaintiffs CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc., and CareFirst Bluechoice, Inc. (together, “CareFirst”, the “CareFirst Plaintiffs” or “Plaintiffs”) filed a lawsuit individually and as representative of all persons or entities in the Class.

The lawsuit alleges that the Defendants engaged in a scheme in violation of state antitrust and consumer protection laws. J&J knowingly, willfully, and improperly maintained its monopoly power and substantially reduced and harmed competition in the market for ustekinumab in the United States by: (1) fraudulently obtaining a method-of-use patent to treat ulcerative colitis, (2) wrongfully acquiring the Momenta biosimilar manufacturing patents, and then (3) asserting and/or enforcing those patents (the ‘307 and Momenta patents) against would-be competitors to unlawfully delay biosimilar competition. Defendants’ scheme delayed the entry of biosimilar competition for J&J’s brand name prescription pharmaceutical drug Stelara by at least fifteen months.

The lawsuit asserts that, as a result of J&J’s alleged unlawful conduct, the prices TPPs paid for the at-issue drugs were higher than they otherwise would have been. Plaintiffs seek to recover damages in the form of overcharges they allege were caused by Defendants’ conduct. Plaintiffs also seek to recover attorneys’ fees and litigation costs.

Defendants deny all these allegations, including that Plaintiffs or members of the Class are entitled to damages or other relief. The Court has not decided whether the Plaintiffs or Defendants are right. The lawyers for the Plaintiffs will have to prove their claims in Court.

3. Why is this lawsuit a class action?

In a class action lawsuit, one or more persons or entities called “plaintiffs” or “class representatives” sue on behalf of others who have similar claims. Together, all these entities make up the “class” and are called the “class” or “class members.” One court resolves the issues for everyone in the class, except for those class members who exclude themselves from the class.

On December 5, 2025, Judge Jamar K. Walker certified a Class of TPPs, described in more detail in **Question 8** below. The Court also appointed CareFirst as class representatives in this case.

The Court decided that this lawsuit can proceed as a class action because it meets the requirements of Federal Rule of Civil Procedure 23, which governs class actions in federal courts. Specifically, the Court found that:

- The Class is so numerous that joinder of all members is impractical (“numerosity”);
- There are questions of law or fact common to the Class (“commonality”);
- The claims or defenses of the representative parties are typical of the claims or defenses of the Class (“typicality”);
- The representative parties and their lawyers will fairly and adequately protect the interests of the Class (“adequacy”);
- Common legal and factual questions predominate over any questions affecting only individual members of the Class (“predominance”); and
- This class action is the superior method for fair and efficient adjudication of this controversy (“superiority”).

In so doing, the Court found that Plaintiffs sufficiently showed that class wide injury “is provable through common evidence” to the Class and that common issues predominate over individualized inquiries. Common legal and factual questions include:

- Whether J&J willfully and improperly maintained monopoly power over ustekinumab in the United States;
- Whether Mr. Dichter, on behalf of J&J, made material misrepresentations and/or omissions to the U.S. Patent and Trademark Office (PTO) with the specific intent to deceive the PTO;
- Whether Mr. Dichter, on behalf of J&J, obtained the ’307 method-of-use patent by fraud on the PTO;
- Whether J&J intentionally acquired the Momenta biosimilar manufacturing patents to unlawfully delay competition and to unlawfully maintain its monopoly over ustekinumab;
- Whether J&J knowingly and unlawfully enforced the fraudulently obtained ’307 patent against would-be biosimilar competitor, Amgen;
- Whether J&J unlawfully used the ’307 patent and acquired the Momenta biosimilar manufacturing patents to delay ustekinumab biosimilar competition;
- Whether J&J unlawfully excluded competitors and potential competitors from the market for ustekinumab;
- Whether J&J unlawfully delayed or prevented manufacturers of ustekinumab biosimilars from coming to market in the United States;
- Whether J&J improperly maintained monopoly power by delaying biosimilar entry;
- Whether the law requires a definition of a relevant market when direct proof of monopoly power is available, and if so, the definition of the relevant market;

**QUESTIONS? CALL 1-866-963-9975 OR VISIT
WWW.STELARATPPCLASSACTION.COM**

- Whether J&J's activities as alleged herein have substantially affected interstate commerce;
- Whether, and if so to what extent, J&J's conduct caused antitrust injury (i.e., overcharges) to the Plaintiffs and members of the Class; and
- The quantum of aggregate overcharge damages to the Plaintiffs and members of the Class.

A copy of the Court's Opinion and Order may be found at www.StelaraTPPClassAction.com.

THE CLAIMS IN THE LAWSUIT

4. What is the current status of the lawsuit?

On December 5, 2025, the Court certified a Class of indirect purchaser plaintiffs for all purposes including trial and any future settlements, as described in **Question 8**, finding, *inter alia*, that the Plaintiffs' claims were "typical," and Plaintiffs satisfied the "adequacy" element. On December 5, 2025, the Court formally appointed the CareFirst Plaintiffs as class representatives and ordered that this Notice be sent.

The case against Defendants is ongoing. There has been no determination by the Court or a jury that the allegations against Defendants have been proven. *A jury trial is scheduled to begin on January 26, 2026.*

5. Has the Court decided who is right?

No. The Court has not decided in favor of Plaintiffs or Defendants with respect to the pending claims. By authorizing this Notice, the Court is not suggesting that Plaintiffs will win or lose this case. If the claims against J&J are not resolved by a settlement or otherwise, Plaintiffs must prove their claims at trial.

6. What are the Plaintiffs asking for?

Plaintiffs are seeking to recover the damages they claim the Class paid as a result of Defendants' unlawful conduct. If Plaintiffs prevail at trial, they will be entitled to recover potentially double or triple the amount of damages that Plaintiffs are able to prove for the Damages Class. Plaintiffs will also seek attorneys' fees and litigation costs.

7. Is there any money available now?

No. The Court has not yet decided whether Defendants did anything wrong, and Plaintiffs have not settled their claims against the Defendants. There is no guarantee that money or benefits will ever be obtained. If they are, members of the Class will be notified regarding how to obtain a share of that money.

WHO IS IN THE CLASS?

You need to decide whether you are affected by this lawsuit.

QUESTIONS? CALL 1-866-963-9975 OR VISIT
WWW.STELARATPPCLASSACTION.COM.

8. Am I part of the Class?

Third-Party Payors (“TPPs”) are entities (besides the patient) that provide payment for health care expenses, like prescription drug benefits. They include entities such as health insurance companies, self-insured health and welfare plans that make payments from their own funds, and other health benefit providers and entities with self-funded plans that contract with a health insurer or administrator to administer their prescription drug benefits.

Third-Party Payors in this lawsuit include such private entities that may provide prescription drug benefits for current or former public employees and/or public benefits programs, but only to the extent that such a private entity purchased Stelara for consumption by its members, employees, insureds, participants, or beneficiaries. You are a member of the Class if you are a TPP and you purchased or paid for prescription drugs as described below.

Damages Class. All Third-Party Payers that indirectly purchased or paid for, as part of a prescription drug benefit, some or all of the purchase price for Stelara in the Damages Class States or Territories² for personal use by their members, enrollees or beneficiaries from January 1, 2024 through December 31, 2025 (the “class period”).

You are not a member of the Class if you are among the following:

- J&J and its subsidiaries and affiliates;
- federal and state governmental entities;
- Third-Party Payers whose only purchases were made pursuant to any Medicaid plan, whether Fee-for-Service or Managed Medicaid; or
- Any entity who excluded themselves (*see* Questions 11-12).

If you fit within the definition of the Class, you will be considered a member of the Class unless you timely and fully comply with the instructions to exclude yourself from the Class as set forth below.

If you are not sure whether you are included, you may call, email, or write to the lawyers in this case at the telephone numbers, email addresses, or addresses listed in **Question 13** below.

YOUR RIGHTS AND OPTIONS AS A MEMBER OF THE CLASS

9. What are my legal rights and options in this case?

If you fit within the definition of the Class, you have to decide whether to stay in the Class represented by the Plaintiffs and Class Counsel or ask to be excluded. **You have to decide this now.** Either choice will have consequences, which you should understand before making your

² The Damages Class States or Territories are Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Maryland, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Puerto Rico, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin.

decision.

10. What happens if I do nothing at all?

If you fit within the definition of the Class, and you do nothing, then you will remain in the Class. You will keep the right to a share of any recovery that may come from a trial or settlement with Defendants in this lawsuit as to that Class. You will not be able to start your own lawsuit against any of the Defendants relating to the legal issues or claims in this case for the Class. All of the Court's orders concerning the Class will apply to you and legally bind you. **If you wish to remain in the Class, you do not need to do anything at this time.**

11. Why would I ask to be excluded from the Class?

If you exclude yourself from the Class – also known as “opting out” of the Class – you are able to file or be part of another lawsuit against Defendants relating to the same claims in this lawsuit. If you exclude yourself from the Class, you will not be legally bound by any of the Court's orders concerning the claims of the Class against Defendants in this class action, judgment, or release entered in this class action as to the Class. You should consider that if you exclude yourself from the Class, then, if the Class does obtain money or benefits as a result of trial or a settlement with the Defendants, you will not share in the money or benefits going to the Class.

If you decide to pursue a claim on your own, you should promptly contact your lawyer to determine whether such a claim, if filed now, may be time-barred by the statute of limitations (in whole or in part).

12. How do I ask the Court to exclude me from the Class?

If you want to exclude yourself from the Class, you must send a letter via First-Class U.S. Mail or emailed to the Notice Administrator below stating that you want to exclude yourself from the Class in *CareFirst of Maryland v. Johnson & Johnson*, No. 23-cv-00629 (E.D. Va.).

Your request for exclusion must include: (i) the entity name, address, and IRS EIN; (ii) the name and title of the entity representative; (iii) the name of this case, *CareFirst of Maryland v. Johnson & Johnson*, No. 23-cv-00629 (E.D. Va.); and (iv) a statement, signed by an authorized representative, that you are a member of the Class and that you wish to be excluded. Any Third-Party Payor included in the Class that does not submit a valid request for exclusion that provides all the necessary information will be bound by the outcome of the case.

Your exclusion request letter may be emailed to the Notice Administrator at Info@StelaraTPPClassAction.com or mailed to:

Mailing address (**Exclusions ONLY**):
Stelara TPP Litigation
c/o A.B. Data, Ltd.
P.O. Box 173001
Milwaukee, WI 53217

QUESTIONS? CALL 1-866-963-9975 OR VISIT
WWW.STELARATPPCLASSACTION.COM

Mailing address (all other correspondence):
Stelara TPP Litigation
c/o A.B. Data, Ltd.
P.O. Box 173136
Milwaukee, WI 53217

The letter **must** be postmarked or emailed no later than January 22, 2026.

Any dispute concerning whether your request to be excluded is valid will be resolved by the Court. You may hire your own lawyer and be heard in any such dispute.

THE LAWYERS REPRESENTING THE CLASS

13. Do I have a lawyer in this case?

On December 5, 2025, the Court found that Class Counsel is qualified, has extensive experience litigating similar antitrust class actions, and would adequately represent the Class. On December 5, 2025, the Court formally appointed the following lawyers to serve as lead Class Counsel and represent you and the members of the Class:

Hannah W. Brennan
Abbye R. K. Ognibene
HAGENS BERMAN SOBOL SHAPIRO LLP
One Faneuil Hall Square, 5th Floor
Boston, MA 02109
Telephone: (617) 482-3700
hannahb@hbsslaw.com
abbyeo@hbsslaw.com

Peter D. St. Phillip
LOWEY DANNENBERG, P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Telephone: (914) 997-0500
PStPhillip@lowey.com

You will not be personally charged for the services of these lawyers in litigating this case against the Defendants.

14. Should I hire my own lawyer?

You do not need to hire your own lawyer if you remain in the Class because the lawyers appointed by the Court are working on your behalf. You may hire a lawyer and enter an appearance through your lawyer at your own expense if you so desire.

15. How will the lawyers be paid?

QUESTIONS? CALL 1-866-963-9975 OR VISIT
WWW.STELARATPPCLASSACTION.COM

If Class Counsel achieves a recovery for the Class, the Court will be asked to approve reasonable fees and expenses for the lawyers who worked on the case and reimburse them for the litigation expenses they have advanced on behalf of the Class. If the Court grants Class Counsel's requests, fees and expenses would either be deducted from any money obtained for the Class or paid separately by the Defendants. Members of the Class will not have to pay any attorneys' fees or expenses.

THE TRIAL

16. How and when will the Court decide who is right?

If the claims against the Defendants are not resolved by a settlement or otherwise, Class Counsel will have to prove Plaintiffs' claims at a trial by jury. That trial is scheduled to commence on January 26, 2026, at the Walter E. Hoffman United States Courthouse, 600 Granby St., Norfolk, VA 23510. During the trial, the jury will hear evidence about whether Plaintiffs are right about the claims in the lawsuit. There is no guarantee that Plaintiffs will win, or that Plaintiffs will get any money for the Class. Any judgment will be binding on all members of the Class who have not opted out, regardless of who wins.

17. Do I have to come to the trial?

No, you do not need to attend the trial. Class Counsel will present the case for Plaintiffs and the Class, and counsel for the Defendants will present the defenses. You and/or your own lawyer (if you choose to hire one) are welcome to attend the trial at your own expense.

18. Will I get money after the trial?

If Plaintiffs obtain money or benefits as a result of the trial or a settlement for the Class, additional notice will be sent with information about how members of the Class may participate. We do not know if or when this will occur or how long this will take.

GETTING MORE INFORMATION

19. Are more details available?

For more detailed information about this litigation, please refer to the papers on file in this litigation, which may be inspected at the Office of the Clerk, United States District Court for the Eastern District of Virginia, Walter E. Hoffman United States Courthouse, 600 Granby St., Norfolk, VA 23510 during regular business hours of each business day. You may also get additional information by calling or writing to Class Counsel as indicated above, by visiting www.StelaraTPPClassAction.com (which provides copies of some key pleadings), or by contacting the Notice Administrator at the following:

Mailing address (**Exclusions ONLY**):

**QUESTIONS? CALL 1-866-963-9975 OR VISIT
WWW.STELARATPPCLASSACTION.COM.**

Stelara TPP Litigation
c/o A.B. Data, Ltd.
P.O. Box 173001
Milwaukee, WI 53217

Mailing address (all other correspondence):
Stelara TPP Litigation
c/o A.B. Data, Ltd.
P.O. Box 173136
Milwaukee, WI 53217

Phone: 1-866-963-9975

Email: info@StelaraTPPClassAction.com

DATED: December 5, 2025

**BY ORDER OF THE UNITED STATES DISTRICT
COURT FOR THE EASTERN DISTRICT OF
VIRGINIA**

**PLEASE DO NOT WRITE TO OR CALL THE COURT OR THE CLERK'S OFFICE
FOR INFORMATION. INSTEAD, PLEASE DIRECT ANY INQUIRIES TO ANY OF
THE CLASS COUNSEL LISTED ABOVE IN QUESTION 13.**